New arrivals mark major step in Kaiser Permanente's expanded relationships with HCA HealthONE and CommonSpirit Health
DENVER, July 7, 2025 /PRNewswire/ -- Kaiser Permanente welcomed...
SACRAMENTO, Calif., July 7, 2025 /PRNewswire/ -- Despite pleas from families throughout California, who have voiced their concerns about exposing patients to substance-abusing doctors,...
AAP, ACP, APHA, IDSA, MPHA, and SMFM Join Together to Stop Assault on Public Health
BOSTON, July 7, 2025 /PRNewswire/ -- Today, the American Academy...
PALM BEACH GARDENS, Fla., July 7, 2025 /PRNewswire/ -- Better by MTA, the leading medical tourism platform, is proud to spotlight its distinguished Platinum Members—organizations...
SANTA MONICA, Calif., July 7, 2025 /PRNewswire/ -- Lifeforce, the world's largest longevity medicine platform, and Toku, a health technology company using AI to...
The FARAPULSE PFA System now approved for pulmonary vein and posterior wall ablation in patients with persistent atrial fibrillation
MARLBOROUGH, Mass., July 7, 2025 /PRNewswire/...
ORLANDO, Fla., July 3, 2025 /PRNewswire/ -- The Villages Health ("TVH"), the trusted healthcare system for The Villages retirement community in Florida, today announced...
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.
In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds. The release explores the evolving role of compounded therapeutics, shifts in consumer behavior toward remote prescribing, and how new formulations align with the growing interest in safe, physician-directed care for weight management.
The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...
The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...